Plasma therapy is a promising treatment against coronaviruses, and many rare other and serious disorders. The blood that is donated by the donor is processed in a processing facility to obtain plasma. Similarly, for the treatment of coronavirus-infected patients, the plasma is isolated from the donor. The donor is also the patient who has recovered from the infection. The donor plasma consists of antibodies that were generated in order to fight the antigens, i.e., the coronavirus. The blood from the donor is processed in processing centers and then injected into the blood of the patients.

Market Dynamics

Regulatory authorities are interested in conducting clinical trials for the development of new treatment options for coronavirus infected patients. For instance, on April 18, 2020, The Drug Controller General of India (DCGI) accepted the proposal of the Indian Council of Medical Research (ICMR), the apex body in India for the formulation, coordination, and promotion of biomedical research, for conducting clinical trials of convalescent plasma in COVID-19 patients. The ICMR has submitted a list of institutes that are interested in the trial. In convalescent plasma therapy, the antibodies are recovered from the blood of patients who have recovered from COVID-19 and injected into the blood of injected patients. The clinical trial aims to assess the efficacy of convalescent plasma to limit complications in COVID-19 patients and to evaluate the safety of treatment with anti SARS-CoV-2 plasma in coronavirus-infected patients. The rising number of clinical trials is expected to increase treatment options for coronavirus infected patients and spur global plasma therapy market growth during the forecast period.

Companies are receiving approvals from regulatory authorities for the setup of a new manufacturing facility. For instance, in 2021, Takeda Pharmaceutical Company Limited received approval from the U.S Food and Drug Administration (U.S FDA) for its new pharmaceutical manufacturing facility near Covington, Georgia. The facility will produce FLEXBUMIN 25% [Albumin (Human), USP, 25% Solution]. The medicine is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome, and nephrosis, cardiopulmonary bypass surgery, and hemolytic disease of newborns. The new facility will expand the product portfolio of the company which is expected to favor the global plasma therapy market growth during the forecast period.international distributors.

Key features of the study:

• This report provides an in-depth analysis of the global plasma therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global plasma therapy market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Octapharma AG, Top Bio Group Co., Ltd,  Bio Products Laboratory Ltd, Kedrion S.p.A, Grifols, S.A,  CSL, Biotest AG, Takeda Pharmaceutical Company Limited, DePuy Synthes (A subsidiary of Johnson & Johnson Services, Inc.), Regen Lab SA, LFB S.A, ImmunoTek Plasma.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global plasma therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma therapy market.

Detailed Segmentation:

• Global Plasma Therapy Market, By Type:
  • Pure PRP
  • Leucocyte-rich PRP
  • Pure Platelet-rich Fibrin (PRF)
  • Leukocyte-rich Fibrin (L-PRF)
• Global Plasma Therapy Market, By Appication:
  • Infectious Diseases
  • Dental
  • Nerve Injury
  • Cardiac Muscle Injury
  • Other Applications
• Global Plasma Therapy Market, By End user:
  • Hospitals and Clinics
  • Research Institutes
  • Others
• Global Plasma Therapy Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Octapharma AG
  • Top Bio Group Co., Ltd
  • Bio Products Laboratory Ltd
  • Kedrion S.p.A
  • Grifols, S.A
  • Cochin Shipyard Limited
  • Biotest AG
  • Takeda Pharmaceutical Company Limited
  • DePuy Synthes (A subsidiary of Johnson & Johnson Services, Inc.)
  • Regen Lab SA
  • LFB S.A
  • ImmunoTek Plasma